Clinical Trial Update: Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating avelumab with hypofractionated radiotherapy in relapsed/refractory multiple myeloma; study terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myeloma, Multiple, Myeloma-Multiple | Phase 2 | Status: TERMINATED | Results posted: 2021-04-20